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Abstract
Purpose Several genomic tests have recently been devel-
oped to identify the primary tumour in cancer of unknown
primary tumour (CUP). However, the value of identifying
the primary tumour in clinical practice for CUP patients
remains questionable and difficult to prove in randomized
trials.
Objective We aimed to assess the clinical and economic
value of primary tumour identification in CUP using a
retrospective matched cohort study.
Methods We used the Manitoba Cancer Registry to iden-
tify all patients initially diagnosed with metastatic cancer
between 2002 and 2011. We defined patients as having
CUP if their primary tumour was found 6 months or more
after initial diagnosis or never found during the course of
disease. Otherwise, we considered patients to have meta-
static cancer from a known primary tumour (CKP). We
linked all patients with Manitoba Health databases to
estimate their direct healthcare costs using a phase-of-care
approach. We used the propensity score matching tech-
nique to match each CUP patient with a CKP patient on
clinicopathologic characteristics. We compared treatment
patterns, overall survival (OS) and phase-specific health-
care costs between the two patient groups and assessed
association with OS using Cox regression adjustment.
Results Of 5839 patients diagnosed with metastatic cancer,
395 had CUP (6.8%); 1:1 matching created a matched
group of 395 CKP patients. CUP patients were less likely
to receive surgery, radiation, hormonal and targeted ther-
apy and more likely to receive cytotoxic empiric
chemotherapeutic agents. Having CUP was associated with
reduced OS (hazard ratio [HR] 1.31; 95% confidence
interval 1.1–1.58), but this lost statistical significance with
adjustment for treatment differences. CUP patients had a
significant increase in the mean net cost of initial diag-
nostic workup before diagnosis and a significant reduction
in the mean net cost of continuing cancer care.
Conclusion Identifying the primary tumour in CUP
patients might enable the use of more effective therapies,Electronic supplementary material The online version of this
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improve OS and allow more efficient allocation of
healthcare resources.
Key Points for Decision Makers
Cancer of unknown primary tumour (CUP) is the
fifth most common cancer type in patients presenting
with metastatic cancer.
Compared with patients with metastatic cancer of
known primary, patients with CUP receive fewer
site-specific cancer treatments, have reduced overall
survival, and use more healthcare resources for
diagnostic workup but less healthcare resources for
cancer care.
Identifying the primary tumour in CUP patients
might enable the use of more precise anticancer
therapy, improve overall survival and allow more
efficient allocation of healthcare resources.
The use of accurate genomic tests to help identify the
primary tumour in CUP might be clinically and
economically warranted.
1 Introduction
Approximately 15% of all new cancers present with
metastases at time of diagnosis [1]. Primary site determi-
nation for metastatic cancers is the starting point to define
standard-of-care patient management. In approximately
two-thirds of these cases, the primary tumour becomes
apparent early during the course of the initial diagnostic
workup [2]. The remaining metastatic cancers represent
challenging cases as tumours of uncertain primary origin.
For these cases, pathologists and oncologists often under-
take a comprehensive diagnostic workup that may include
cytogenetic studies, electron microscopy, endoscopies and
immunohistochemical (IHC) analysis [2, 3]. Although
clinical and pathologic investigations are recommended to
be sign and symptom guided [2, 3], they often require a
longer hospital stay accompanied by painful and distress-
ing investigations and may incur increased costs for the
healthcare system [4, 5]. However, a primary tumour site is
identified in \30% of these cases [6, 7]. Consequently,
over 6800 cases with histologically proven metastatic
cancer of unknown primary origin (CUP) are diagnosed
annually in Canada despite diagnostic assessment.
Although it is accepted that CUP is a heterogeneous
collection of metastatic malignancies [6], there is no
consensus on whether CUP is simply a group of metastatic
tumours with undetected primary tumours or a distinct
entity with specific genetic characteristics [6]. Clinically
occult primary tumours have subsequently been anatomi-
cally detected at autopsy in about 75% of CUP patients [8].
In addition, approximately 7% of CUP patients have their
latent primary (LP) tumour clinically detected months to
years after initial diagnosis [9]. Most metastatic tumour
biopsies from CUP patients are completely undifferentiated
or poorly differentiated, with the majority being adeno-
carcinomas, but other histologies have also been diagnosed
(e.g. lymphoma, melanoma, sarcoma) [1, 10].
In the absence of a specific primary tumour diagnosis,
treatment guidelines vary [3]. When appropriate, CUP
patients are typically treated with empirical cytotoxic
chemotherapy regimens [11, 12]. Despite this, CUP
patients have a poor prognosis, with median survival typ-
ically ranging from 7 to 11 months [6].
In recent years, the emergence of gene expression
tumour-profiling assays (messenger RNA [mRNA] or
microRNA platforms) as adjuncts to current clinicopatho-
logic evaluations has offered the potential to correctly
identify the primary tumour in about 90% of patients with
CUP [7, 13–26]. This breakthrough, coupled to the recent
emergence of targeted drugs for patients with known pri-
mary tumour (CKP) fuelled hopes for a revamp of CUP
management [27–29]. Although the clinicopathologic pre-
sentation of CUP patients may differ from that of patients
with CKP, there does not seem to be a major disparity in
the response rates and the outcomes between these two
patient groups after the primary tumour is defined and
tumour-specific therapies are administered [29]. However,
the impact of primary tumour identification via gene
expression profiling on clinical outcomes for patients with
CUP remains uncertain and difficult to prove in random-
ized trials because of a combination of ethical, clinical and
logistical considerations [29–31]. Additional clinical evi-
dence is necessary to optimize a precision medicine strat-
egy as a standard of care for patients with CUP. In addition,
the impact of primary tumour identification on the cost of
care throughout the course of metastatic disease will be an
important element in the formulation of new provincial
guidelines and reimbursement policies for CUP manage-
ment and necessary to inform healthcare resource alloca-
tion and fiscal planning for the prospective precision
medicine era of care for CUP.
In this study, we aimed to estimate the potential clinical
and economic value of primary tumour identification in
CUP using heath administrative databases from the Cana-
dian province of Manitoba to carry out a propensity score
matched-cohort analysis in which we evaluated differences
in clinical and economic outcomes between patients with
CUP and their matched counterparts with CKP.
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2 Patients and Methods
2.1 Data Sources and Identification of Study
Population
The Manitoba Cancer Registry (MCR) and Provincial
Pharmacy program at CancerCare Manitoba (CCMB) and
Manitoba administrative databases held by Manitoba
Health, including the Hospital Discharge Database,
Physician Claims Database and the Drug Program Infor-
mation Network (DPIN), served as the data sources for this
analysis. A full description of these databases and their
contents has been reported elsewhere [30–33].
We have previously used the MCR to identify a cohort
of patients diagnosed initially with metastatic cancer dur-
ing the period from 1 January 2002 to 31 December 2011
[34] and identify when these patients had their primary
tumour diagnosed during the course of their disease. The
cohort was limited to Manitoba residents who had under-
gone clinical and pathological diagnostic evaluation in
Manitoba and with no history of other malignancy at initial
diagnosis. A minimum of 2-year follow-up information
from the time of initial diagnosis was available for each
patient. Follow-up information included diagnosis of sec-
ond primary, cancer treatments (e.g. surgical and thera-
peutic radiology procedures, systemic therapy and
palliative care) and death. Full details regarding the iden-
tification of this metastatic patient population and the
process by which we identified when primary tumours were
diagnosed are reported elsewhere [34].
For this analysis, we used this metastatic patient popu-
lation to identify all patients who had their metastatic
disease histologically confirmed and survived at least
6 months following their initial cancer diagnosis. This
6-month window was used to ensure that patients would
have had reasonable time during the early course of their
metastatic disease to undergo all necessary clinical and
pathological diagnostic evaluations (i.e. diagnostic
workup) and had their primary tumour sites diagnosed [9].
We stratified patients by their primary tumour diagnostic
status (CUP vs. CKP). We defined patients as having CUP
if their primary tumour was initially unidentified (i.e. In-
ternational Classification of Diseases for Oncology [ICD-
O] code C80.9) and either had their LP tumour diagnosed
at least 6 months after their initial diagnosis or who never
had their LP tumour diagnosed during the 2-year follow-up
period. The 6-month window was used to ensure the
identification of the LP tumour was not the result of
extension in the initial diagnostic workup and is considered
conservative compared with other attempts at identifying
CUP using a 2-month window [9]. We defined patients as
having CKP if their primary tumour was initially identified
during the 6 months after their initial diagnosis and no
change was detected in their primary tumour diagnostic
status later during the 2-year follow-up period.
2.2 Linkage with the Provincial Pharmacy Program
Database at CCMB and Manitoba
Administrative Databases
We linked the two patient groups with the Provincial
Pharmacy Program of CCMB and Manitoba Health’s
administrative databases to validate all cancer therapy data
captured by the MCR; to collect additional information on
types of radiotherapy and systematic therapy agents; to
measure co-morbidity; and to estimate direct healthcare
costs. To protect confidentiality, the linkage was performed
with a scrambled unique health number using anonymized
versions of these databases. Records of these databases for
each patient in the study cohort were available between
3 years before and 2 years after initial cancer diagnosis.
2.3 Comorbidity Index
We determined co-morbidity from the Hospital Discharge
Database and the Physician Claims Database through
diagnoses that were recorded for each patient in the study
cohort during all patient hospital stays and physician
claims between 3 years before and 6 months after initial
cancer diagnosis. We used co-morbid diagnoses coded
using the Charlson Co-morbidity Index, excluding cancer
diagnoses, which has been used elsewhere [32–34].
We also used the Physician Claims Database to collect
information on diagnostic tests and procedures undertaken
during the diagnostic workup (defined as the period from
6 months before to 6 months after initial cancer diagnosis)
for all identified patients diagnosed with metastatic cancer.
The diagnostic tests and procedures recorded in the
Physician Claims Database include the following: endo-
scopies, diagnostic ultrasound scans, X-rays, computerized
axial tomography (CT) scans, magnetic resonance imaging
(MRI) scans, diagnostic isotope procedures, fine and core
needle biopsies, pulmonary function tests, lumbar puncture
(spinal tap), dermatoscopy, guaiac faecal occult blood test,
gynaecological physical examination, Papanicolaou (Pap)
test, and dilatation and curettage.
2.4 Direct Healthcare Costs
The direct costs of healthcare services comprised inpatient
and 1-day procedure stays, physician and other healthcare
provider services, prescription drugs and intravenous
oncology drugs. The costs of these services and drugs are
all publicly funded in Manitoba and recorded in the
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Hospital Discharge Database [35, 36], Physician Claims
Database, DPIN database and Provincial Pharmacy Pro-
gram of CCMB database. We determined the healthcare
costs from all records of these databases for each patient in
the study cohort between 3 years before and 2 years after
initial cancer diagnosis. All costs are expressed in Cana-
dian dollars (CAD), year 2016 values, using the Bank of
Canada inflation calculator [37].
We estimated the costs of various service and drug cate-
gories using a phase-of-care approach [38–41]. Costs of care
for patients in the cohort were divided into five clinically
relevant phases of care: (1) usual care before the onset of signs
of illness; (2) initial diagnostic workup before diagnosis; (3)
continuing diagnostic workup after diagnosis and initial
cancer care; (4) continuing cancer care; (5) last 6 months of
life. The ‘‘usual care before the onset of signs of illness’’ phase
consisted of the time between 3 years and 6 months before
diagnosis. We defined the ‘‘initial diagnostic workup before
diagnosis’’ phase as the 6 months before diagnosis and the
‘‘continuing diagnostic workup after diagnosis and initial
cancer care’’ phase as the 6 months after diagnosis. Among
the patients who died, the ‘‘last 6 months of life’’ phase was
defined as the final 6 months of life. The ‘‘continuing cancer
care’’ phase consisted of the time between the ‘‘continuing
diagnostic workup after diagnosis and initial cancer care’’ and
‘‘last 6 months of life’’ phases. Because all patients included
in our study cohort survived at least 6 months following their
initial cancer diagnosis (i.e. by our inclusion criteria), we first
allocated costs to the first two phases of care (‘‘usual care
before the onset of signs of illness’’ and ‘‘initial diagnostic
workup before diagnosis) and the ‘‘last 6 months of life’’
phase. Then, we allocated costs to the ‘‘continuing diagnostic
workup after diagnosis and initial cancer care’’ phase, and any
remaining costs were allocated to the ‘‘continuing cancer
care’’ phase. To determine whether costs incurred during the
last 6 months of the 2-year follow-up period should be allo-
cated to the ‘‘last 6 months of life’’ phase or to the ‘‘contin-
uing cancer care’’ phase, it was necessary to collect from the
MCR an additional 6 months of death information following
the 2-year follow-up from the time of initial diagnosis.
2.5 Statistical Analysis
In our primary analysis, we used the propensity score-
matching method to build comparable CUP and CKP
groups in terms of observable characteristics [42–44]. Full
details on propensity score matching are provided as
Electronic Supplementary Material (ESM).
We constructed 2-year Kaplan–Meier curves to examine
the cumulative probability of overall survival (OS) for the
two patient groups. The curves were compared using the
log-rank test statistic. We then used a Cox proportional
hazards model to test the effect of the diagnostic status of
primary tumour (CUP vs. CKP) on the 2-year OS by cal-
culating the hazard ratio (HR) for death with associated
95% confidence intervals (CIs) for CUP versus CKP.
Receipt of cancer treatments (surgery [yes vs. no], radio-
therapy [yes vs. no], systematic therapy [yes vs. no]), time
to receive cancer treatments following initial diagnosis
(number of months to surgery, radiotherapy and
chemotherapy), receipt of biological targeted therapy (tar-
geted biological therapy ? chemotherapy vs. chemother-
apy alone) were all tested for associations with OS and
tested for their effect on the calculated HR for CUP versus
CKP by adjusting the Cox proportional hazards model for
these treatment covariates. We also examined whether the
association of these treatment covariates with OS differed
in CUP versus CKP by testing for interactions between
treatment covariates and the diagnostic status of primary
tumour (CUP vs. CKP).
In secondary analyses, we used three different methods
to adjust for differences in baseline characteristics between
the CUP group and all patients with CKP in the full cohort
and examined the effect of diagnostic status of primary
tumour (CUP vs. CKP) on the 2-year OS by calculating
adjusted HRs and 95% CIs for CUP versus CKP. First, we
adjusted for the propensity score by including it as a con-
tinuous covariate in a Cox proportional hazards model.
Second, we adjusted for all baseline characteristics by
including them as covariates in a traditional multivariable-
adjusted Cox proportional hazards model. Third, we used a
weighted Cox proportional hazards model, where the
weight assigned for each patient was based on the stabi-
lized inverse propensity score, as described elsewhere [43].
Within each phase of care and for each cost category, we
calculated the cost per day for each patient in our cohort
and the average cost per day separately for the CUP group,
matched CKP group and all patients with CKP in the full
cohort. We then estimated the average net cost per day for
each phase of care following the ‘‘usual care before the
onset of signs of illness’’ phase as the difference in average
cost per day between the ‘‘usual care before the onset of
signs of illness’’ phase and each of the following phases of
care. We estimated the average net cost of an entire phase
of care as the average net cost per day multiplied by the
average number of days spent in that phase of care. We
also calculated these cost estimates for the overall health-
care utilization by combining all cost categories.
3 Results
We identified 5839 patients who were initially diagnosed
with metastatic cancer during the period from 1 January
2002 to 31 December 2011 and met our study inclusion
criteria. Of those, 395 had CUP (6.8%) and 5444 (93.2%)
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had CKP (Table 1). Among those patients with CUP, 219
were women and 176 were men, accounting for 8.8% of all
women and 5.3% of all men diagnosed with metastatic
cancer, respectively (mean difference 3.5%, 95% CI
2.2–4.9; p\ 0.0001; Table 1). Among those patients with
CUP, 169 (42.8%) had their LP tumour diagnosed later,
after 6 months from their initial diagnosis, and 226
(57.2%) never had their LP tumour diagnosed during the
2-year follow-up period. Table 2 shows the final classifi-
cation of primary tumour site later in the course of meta-
static disease for 395 patients initially diagnosed with CUP.
Prior to matching, patients with CUP presented with
clinicopathological features distinct from those of their
counterparts of all patients with CKP (Table 3). Using 1:1
matching on the estimated propensity score, we matched
the CUP group of 395 patients with a CKP group of 395
patients. No CUP cases were dropped due to poor match
quality. Table 3 shows the baseline patient and tumour
characteristics of the matched CKP group as compared
with the CUP group. As a result of matching, we elimi-
nated differences between the two groups in age, sex, year
of initial diagnosis, co-morbidity score, grade differentia-
tion, histology and number and type of metastatic sites
(Table 3).
The diagnostic tests and procedures undertaken during
the diagnostic workup for the CUP group compared with
the CKP matched group and all patients with CKP in our
cohort are described in Table S1 in the ESM. During the
diagnostic workup, compared with the matched CKP
group, the CUP group were more likely to receive colo-
noscopy, gastroscopy and/or esophagogastroduo-
denoscopy, laryngoscopy and pharyngoscopy, laparotomy,
panendoscopy (respiratory system); CT scans of the neck,
abdomen and pelvis, and spine; MRI scans of the spine;
ultrasound scans of the chest, abdomen and retro-
peritoneum, female pelvis, miscellaneous scans (Doppler
studies); thyroid biopsy; and mammography (Table S1).
However, CUP patients were less likely to receive bron-
choscopy, mediastinoscopy, proctosigmoidoscopy and
pulmonary function tests than were the matched CKP
group (Table S1). Other diagnostic tests and procedures
were similar between the two patient groups (Table S1).
3.1 Treatment Characteristics
Compared with matched CKP patients, patients with CUP
were less likely to have surgical resections (mean differ-
ence 18.5%; 95% CI 11.8–25; p\ 0.0001), receive
radiotherapy (mean difference 9.1%; 95% CI 2.5–15.7;
p = 0.007) and receive systemic therapy (mean difference
9.1%; 95% CI 2.2–16; p = 0.009) (Table 4). Time to any
of these therapies after initial diagnosis did not differ sig-
nificantly between the CUP and matched CKP groups
(Table 4). Among all patients who received systemic
therapy, CUP patients were less likely than matched
patients with CKP to receive hormone therapy (mean dif-
ference 4.5%; 95% CI 1.9–7.1; p = 0.002) and biological
targeted therapy (mean difference 13.9%; 95% CI
5.3–22.4; p = 0.002) but more likely to receive platinum
drugs (mean difference 11.2%; 95% CI 1.4–20.9;
p = 0.02) and taxanes (mean difference 18%; 95% CI
8.2–27.7; p = 0.0003) (Table 4). Table 4 shows the treat-
ment characteristics of the CUP group, matched CKP
group and all patients with CKP.
3.2 Survival Outcomes
The OS of patients with CUP was worse than that of
matched CKP patients (2-year OS 41.7 vs. 50.4%,
p = 0.005, Fig. 1; HR 1.31, 95% CI 1.1–1.58, p = 0.005,
Table 1 Primary tumour site of
5839 patients diagnosed with
metastatic cancer by sex
Primary tumour sites Men (n = 3344) Women (n = 2495) All (n = 5839)
Gastrointestinal tumours 960 (28.7) 613 (24.6) 1573 (27)
Lung and pleural tumours 598 (17.9) 603 (24.2) 1201 (20.6)
Male genital system 676 (20.2) – 676 (11.6)
Lymphoma tumours 264 (7.9) 211 (8.5) 475 (8.1)
Unknown primary tumour site 176 (5.3) 219 (8.8) 395 (6.8)
Head and neck tumours 282 (8.4) 90 (3.6) 372 (6.4)
Urological tumours 248 (7.4) 92 (3.7) 340 (5.8)
Breast tumours 1 (\ 0.1) 281 (11.3) 282 (4.8)
Gynaecologic tumours – 265 (10.6) 265 (4.5)
Melanoma (skin) tumours 60 (1) 26 (1) 86 (1.5)
Endocrine tumours 38 (1.1) 44 (1.8) 82 (1.4)
Bone and soft tissue sarcoma tumours 35 (1) 41 (1.6) 76 (1.3)
Other known primary tumours 6 (0.2) 10 (0.4) 16 (0.3)
Data are presented as n (%)
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Table 5). In a Cox proportional hazard regression analysis,
having a CUP compared with CKP became a non-signifi-
cant independent predictor of OS when controlling for use
of surgery, radiotherapy and systematic therapy (Table 5).
In this analysis, receipt of surgical resection and systemic
therapy were significant independent predictors of OS
(Table 5). No interactions between treatments and primary
tumour status (CUP vs. CKP) were identified.
In subgroup analysis that included only patients treated
with systematic therapy from the CUP and matched CKP
groups and controlled for use of surgery and radiotherapy,
receipt of a biological targeted therapy was associated with
survival advantage (HR 0.52; 95% CI 0.31–0.88;
p = 0.01). The type of chemotherapeutic agents received
(platinum with or without taxanes vs. other chemothera-
peutic combinations) and receipt of hormone therapy were
not independent significant predictors of OS. No interac-
tions between these therapies and primary tumour status
(CUP vs. CKP) were identified.
Unadjusted and adjusted Cox proportional hazard
regression analyses that compared the OS of the CUP
group (n = 395) with that of all patients with CKP
(n = 5444) revealed similar results (Fig. 1; Table 5).
3.3 Direct Costs of Healthcare Utilization
The estimated mean net total costs for the CUP group and
matched CKP group were $CAN38,900 and $CAD38,850,
respectively. The mean net costs in the ‘‘initial diagnostic
workup before diagnosis’’ phase, ‘‘continuing diagnostic
workup after diagnosis and initial cancer care’’ phase,
‘‘continuing cancer care’’ phase, and ‘‘last 6 months of
life’’ phase accounted for 20.2, 46.5, 14.8 and 18.5% of the
total mean net cost for the CUP group, respectively, and for
8.7, 49.5, 26 and 16% of the total mean net cost for the
matched CKP group, respectively. Figure 2 depicts the
mean cost per day within each phase of care and the mean
net cost of an entire phase of care by cost category for the
CUP group, matched CKP group and all patients with CKP
in the full cohort.
Within the ‘‘initial diagnostic workup before diagnosis’’
phase, compared with matched CKP patients, CUP patients
had a significant increase in the mean net cost of inpatient
and 1-day procedure stays (mean difference $CAD2960;
95% CI 650–5270), a significant increase in the mean net
cost of physician and other healthcare provider services
(mean difference $CAD1425; 95% CI 1008–1840), and a
significant increase in the mean net cost of prescription
drugs (mean difference $CAD241; 95% CI 75–406),
accounting for a significant increase in the mean net cost of
overall healthcare utilization within this phase of care
(mean difference $CAD4622; 95% CI 1730–7520)
(Fig. 2).
Within the ‘‘continuing diagnostic workup after diag-
nosis and initial cancer care’’ phase, compared with mat-
ched CKP patients, CUP patients had a non-significant
Table 2 Final classification of primary tumour later in the course of metastatic disease for 395 patients initially diagnosed with cancer of
unknown primary tumour
Initial classification of primary tumour site
early in the course of metastatic disease
Final classification of primary tumour site
later in the course of metastatic disease
Patients, n (%)
Unknown primary tumour (n = 395) Unknown primary tumour 226 (57.2)
Ovary 23 (5.8)
Colon and rectum 22 (5.5)
Non-small cell lung 22 (5.5)
Non-Hodgkin’s lymphoma 19 (4.8)
Buccal cavity and pharynx 14 (3.5)
Pancreas 12 (3)
Bone and soft tissue sarcoma 11 (2.8)
Stomach, small intestine, hepatocellular liver,
and other digestive system
9 (2.3)
Melanoma (skin) 7 (1.8)
Prostate and testicular germ cell 7 (1.8)
Kidney, renal pelvis and ureter 6 (1.5)
Small cell lung and other lung 6 (1.5)
Thyroid and other endocrine system 4 (1)
Breast 3 (0.75)
Other female genital system 3 (0.75)
Other ill-defined sites 1 (0.25)
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Table 3 Baseline patient and tumour characteristics of 5839 patients diagnosed with metastatic cancer by diagnostic status of their primary
tumours
Characteristic Patients with
CUP
(n = 395)
Patients with
CKP
(n = 5444)
p valuea Matched patients
with CKP
(n = 395)b
p valuec
Age at initial diagnosis, years 65.3 ± 13.9
(24–96)
64.3 ± 13.1
(19–103)
0.14 65 ± 13.9
(20–100)
0.9
Year of initial diagnosis
2002–2003 85 (21.5) 949 (17.4) 0.06 84 (21.3) 0.9
2004–2005 75 (19) 1225 (22.5) 71 (18)
2006–2007 85 (21.5) 1185 (21.8) 84 (21.3)
2008–2009 91 (23) 1104 (20.3) 94 (23.8)
2010–2011 59 (15) 981 (18) 62 (15.7)
Sex
Men 176 (44.6) 3168 (58.2) \0.0001 175 (44.4) 0.9
Women 219 (55.4) 2276 (41.8) 220 (55.6)
Grade differentiation or cell indicator
Well differentiated 7 (1.8) 170 (5) \0.0001 9 (2.2) 0.9
Moderately differentiated 20 (5) 1259 (37.2) 21 (5.3)
Poorly differentiated 65 (16.5) 1448 (42.7) 63 (15.9)
Undifferentiated 286 (72.4) 2209 (40.6) 287 (72.6)
T cell/B cell 17 (4.3) 358 (6.6) 15 (3.8)
Histology
Adenocarcinomas 157 (39.7) 2645 (48.6) \0.0001 157 (39.7) 0.9
Squamous cell carcinoma 49 (12.4) 557 (10.2) 51 (12.9)
Mucinous and serous 26 (6.6) 235 (4.3) 27 (6.8)
Undifferentiated carcinoma 114 (28.8) 895 (16.4) 112 (28.3)
Melanoma 11 (2.8) 96 (1.8) 10 (2.5)
Complex mixed and stromal 5 (1.3) 24 (0.4) 6 (1.5)
Transitional cell, ductal lobular medullary, complex epithelial,
soft tissue sarcomas, myomatous, germ cell, miscellaneous bone,
nerve sheath
14 (3.5) 473 (8.7) 13 (3.3)
Hodgkin’s lymphoma, NHLs, other lymphoma 19 (4.8) 475 (8.7) 19 (4.8)
Others 0 44 (0.8) 0
Number of metastatic sites
1 215 (54.4) 2014 (36.9) \0.0001 214 (54.2) 0.9
2 105 (26.6) 1702 (31.3) 105 (26.6)
C3 75 (19) 1728 (31.7) 76 (19.3)
Metastatic sites, frequency (%)
Digestive system 196 (32.2) 1859 (21) \0.0001 193 (31.7) 0.7
Respiratory system 96 (15.8) 1478 (16.7) 102 (16.8)
Bones and joints 68 (11.2) 1207 (13.7) 67 (11)
Brain and other nervous system 24 (3.9) 509 (5.8) 25 (4.1)
Soft tissue (including heart) 19 (3.1) 128 (1.4) 18 (3)
Skin 11 (1.8) 59 (0.7) 9 (1.5)
Lymph nodes 142 (23.3) 2887 (32.7) 143 (23.5)
Ill defined 25 (4.1) 349 (3.9) 26 (4.3)
Others, including buccal cavity and pharynx, breast, female
genital system, male genital system, urinary system,
hematopoietic and reticuloendothelial systems, endocrine system,
and eye and adnexa
28 (4.6) 356 (4) 25 (4.1)
With second primary tumour 18 (4.6) 266 (4.9) 0.7 18 (4.6) 1
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difference in the mean net cost of inpatient and 1-day
procedure stays and physician and other healthcare provi-
der services but had a significant decrease in the mean net
cost of intravenous oncology drugs (mean difference
$CAD870; 95% CI 255–1480) and a significant decrease in
the mean net cost of prescription drugs (mean difference
$CAD340; 95% CI 84–595), accounting for a non-signifi-
cant difference in the mean net cost of overall healthcare
utilization within this phase of care (Fig. 2).
Within the ‘‘continuing cancer care’’ phase, compared
with matched CKP patients, CUP patients had a non-sig-
nificant difference in the mean net cost of inpatient and
1-day procedure stays, a significant decrease in the mean
net cost of physician and other healthcare provider services
(mean difference $CAD580; 95% CI 290–875), a signifi-
cant decrease in the mean net cost of prescription drugs
(mean difference $CAD450; 95% CI 135–760), and a
significant decrease in the mean net cost of intravenous
oncology drugs (mean difference $CAD1912; 95% CI
1090–2740), accounting for a significant decrease in the
mean net cost of overall healthcare utilization within this
phase of care (mean difference $CAD4390; 95% CI
1100–7680) (Fig. 2).
Within the ‘‘last 6 months of life’’ phase, compared
with matched CKP patients, CUP patients had a non-
significant difference in the mean net cost of inpatient and
1-day procedure stays, physician and other healthcare
provider services and intravenous oncology drugs and a
significant increase in the mean net cost of prescription
drugs (mean difference $CAD477; 95% CI 320–610),
accounting for a non-significant difference in the mean
net cost of overall healthcare utilization within this phase
of care (Fig. 2).
Cost analyses that compared the CUP group with all
patients with CKP (n = 5444) across all cost categories
and phases of care revealed similar results (Fig. 2).
4 Discussion
Through a population-based analysis, we found CUP to be
the fifth most common (6.8%) cancer type diagnosed in
patients presenting with metastatic cancer and to be more
common in women (8.8%) than in men (5.3%). The most
common histological subtypes found in CUP were adeno-
carcinoma (40%), undifferentiated carcinoma (29%) and
squamous carcinoma (12%). Although CUP patients
appeared to undergo more diagnostic tests and procedures
during the diagnostic workup than their matched CKP
counterparts, patients with CUP did not have their LP
tumour site identified, except in 42% of patients where it
was discovered at a later phase of care (i.e. after 6 months
from initial cancer diagnosis). The percentage of LP
tumour detection later in the course of the disease in our
CUP group was higher than previously reported estimates
[9], which was likely due to our conservative inclusion
criteria of at least 6-month survival.
Having CUP appears to be associated with less frequent
use of surgical interventions, radiation and hormonal and
biological targeted therapy as well as greater use of non-
selective cytotoxic chemotherapeutic drugs such as plat-
inum drugs and taxanes. There was a significant decrease in
the mean net cost of overall healthcare utilization, includ-
ing the cost of intravenous oncology drugs during the
‘‘continuing cancer care’’ phase. Less exposure to surgery
and biological targeted therapy were independently
Table 3 continued
Characteristic Patients with
CUP
(n = 395)
Patients with
CKP
(n = 5444)
p valuea Matched patients
with CKP
(n = 395)b
p valuec
Charlson co-morbidity scored 0.3 ± 0.7
(0–6)
0.29 ± 0.72
(0–12)
0.8 0.3 ± 0.6 (0–6) 0.9
[0 92 (23.3) 1194 (21.9) 0.5 93 (23.5) 0.9
0 303 4250 305
1 75 941 77
C2 17 253 16
Data are presented as mean ± standard deviation (range) or number of patients (%) unless otherwise indicated
CKP cancer from a known primary tumour, CUP cancer of unknown primary tumour, NHLs non-Hodgkin’s lymphomas
a Patients with CUP (n = 395) vs. all CKP (n = 5444) using Fisher’s exact or Chi squared tests. All statistical tests were two sided, and results
were considered significant at the 5% critical level. Statistical analysis was performed using SAS, version 9.3 (Cary, NC, USA)
b Patients were matched on the estimated propensity score
c Patients with CUP (n = 395) vs. matched CKP (n = 5444) using Fisher’s exact or Chi squared tests
d Co-morbid diagnoses were considered present if they were found during 1 year before and 6 months after the initial diagnosis with cancer
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Table 4 Treatments of 5839 patients diagnosed with metastatic cancer by diagnostic status of their primary tumours
Characteristic Patients with CUP
(n = 395)
Patients with CKP
(n = 5444)
p valuea Matched patients with
CKP (n = 395)b
p valuec
With surgical resection 112 (28.3) 2673 (49.1) \0.0001 185 (46.8) \0.0001
Months between initial cancer diagnosis and
surgical resection
Mean ± SD (range) 1.5 ± 3 (0–20.5) 1.7 ± 3.1 (0–24) 0.6 1.2 ± 1.9 (0–15.8) 0.3
C 0 to\ 3 91 2222 162
C 3 to\ 6 13 256 17
C 6 to\ 12 6 134 5
C 12 to\ 24 2 61 1
With radiotherapy 117 (29.6) 1968 (36.1) 0.009 153 (38.7) 0.006
Months between initial cancer diagnosis and
start of radiotherapy
Mean ± SD (range) 4.1 ± 4.7 (0–23.7) 5.2 ± 5.4 (0–24) 0.01 4.6 ± 4.7 (0–22.9) 0.34
C 0 to\ 3 72 955 78
C 3 to\ 6 17 402 30
C 6 to\ 12 20 379 32
C 12 to\ 24 8 232 13
Type of radiotherapy
Teletherapy 117 (100) 1775 (90.2) 0.001 132 (86.3) \0.0001
Brachytherapy 0 18 (0.9) 4 (2.6)
Teletherapy ? brachytherapy 0 40 (2) 3 (2)
Other types 0 14 (6.9) 14 (9.1)
With systemic therapy 207 (52.4) 3528 (64.8) \0.0001 243 (61.5) 0.009
Type of systemic therapy received
Only CTX with or without biological targeted
therapy
207 (100) 3298 (93.5) 0.0001 232 (95.5) 0.002
HTd ? CTX with or without biological
targeted therapy
0 230 (6.5) 0.0001 11 (4.5) 0.002
Months between initial cancer diagnosis and
start of radiotherapy
Mean ± SD (range) 3 ± 3.6 (0–22.9) 3.4 ± 3.8 (0–23.8) 0.1 3 ± 3.2 (0–18.3) 0.8
C 0 to\ 3 146 2261 162
C 3 to\ 6 36 791 58
C 6 to\ 12 16 295 11
C 12 to\ 24 9 181 12
With information about CTX and biologic
therapy agents received
151 (72.9) 2613 (74) 0.2 180 (74) 0.1
With biological targeted therapy 21 (13.9) 522 (20) 0.06 50 (27.8) 0.002
Type of CTX agents received
Platinum drugse 115 (76.2) 1528 (58.5) \0.0001 117 (65) 0.02
Alkylating agents 3 (2) 44 (1.7) 1 (0.6) 0.3
Antimetabolitesf 78 (51.7) 1316 (50.4) 0.7 88 (48.9) 0.6
Anthracyclinesg 21 (13.9) 420 (16.1) 0.4 20 (11.1) 0.4
Topoisomerase inhibitorsh 41 (27.2) 793 (30.3) 0.4 60 (33.3) 0.2
Taxanesi 59 (39.1) 467 (17.9) \0.0001 38 (21.1) 0.0003
Vinca alkaloids 1 (0.7) 175 (6.7) 0.003 7 (3.9) 0.06
Corticosteroids 4 (2.6) 16 (0.6) 0.004 1 (0.6) 0.2
Other anti-tumour antibioticsj 3 (2) 72 (2.8) 0.6 1 (0.6) 0.3
Type of biological targeted therapy agents
received
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Table 4 continued
Characteristic Patients with CUP
(n = 395)
Patients with CKP
(n = 5444)
p valuea Matched patients with
CKP (n = 395)b
p valuec
Bevacizumab 4 (2.6) 153 (5.9) 0.09 20 (11.1) 0.003
Rituximab 12 (7.9) 295 (11.3) 0.2 22 (12.2) 0.2
Cetuximab 2 (1.3) 26 (1) 0.6 4 (2.2) 0.5
Interferon-alfa-2b 2 (1.3) 14 (0.5) 0.2 2 (1.2) 0.6
Panitumumab 1 (0.6) 18 (0.7) 0.9 0 0.4
Bortezomib 0 7 (0.3) 0.9 0
Other targeted therapy 1 (0.6) 21 (0.8) 0.9 4 (2.2) 0.3
With support drugs to control CTX-associated
side effects or conditions
99 (65.6) 1580 (60.5) 0.2 114 (63.3) 0.7
Data are presented as mean ± SD (range) or number of patients (%) unless otherwise indicated
CKP cancer from a known primary tumour, CTX chemotherapy, CUP cancer of unknown primary tumour, SD standard deviation
a Patients with unknown primary (n = 395) vs. all known primary (n = 5444) using Fisher’s exact or Chi square. All statistical tests were two
sided and results were considered significant at the 5% critical level. Statistical analysis was performed using SAS, version 9.3 (Cary, NC)
b Patients were matched on the estimated propensity score
c Patients with unknown primary (n = 395) vs. matched known primary (n = 5444) using Fisher’s exact or Chi square
d Hormone therapy included abiraterone, buserelin, leuprolide, letrozole, zoladex, and bicalutamide
e Platinum drugs included carboplatin, cisplatin and oxaliplatin
f Antimetabolites included capecitabine, gemcitabine, 5-fluorouracil, and raltitrexed
g Anthracyclines included doxorubicin and epirubicin
h Topoisomerase inhibitors included etoposide and irinotecan
i Taxanes included paclitaxel and docetaxel
j Other agents included dexamethasone, vincristine, streptozocin, cyclophosphamide, and mitomycin
Number of patients at risk
395 395 262 202                                   165
395                                  395                                   293                                  240          199
5,444 5,444 4,049 3,221 2,692
Stratified Log-Rank test p≤ 0.005 at 2 
41.7%
50.4%
49.5%
Fig. 1 Overall survival analyses comparing patients with cancer of unknown primary tumour (CUP) with patients with cancer from a known
primary tumour (CKP)
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Fig. 2 Cost of healthcare utilization for 5839 patients diagnosed with
metastatic cancer by diagnostic status of their primary tumour and
cost category and phase of care. Mean net cost of an entire phase of
care = (mean cost per day in that phase of care - mean cost per day
in the ‘‘usual care before the onset of signs of illness’’ phase) 9 av-
erage number of days spent in that phase of care. Since all patients
included in our study survived at least 6 months following their initial
cancer diagnosis, the three patient groups spent 2.5 years in the
‘‘usual care before the onset of signs of illness’’ phase and 6 months
in the ‘‘initial diagnostic workup before diagnosis’’ phase. In the
‘‘continuing diagnostic workup after diagnosis and initial cancer
care’’ phase, CUP patients, matched CKP patients and all patients
with CKP spent an average of 144 days, 154 and 156 days,
respectively. In the ‘‘continuing cancer care’’ phase, CUP patients,
matched CKP patients and all patients with CKP spent an average of
260, 310 and 301 days, respectively. In the ‘‘last 6 months of life’’
phase, CUP patients, matched CKP patients and all patients with CKP
spent an average of 108, 95 and 97 days, respectively. Asterisk We
used the resource intensity weights [36, 37] recorded for inpatient
stays and day procedure group weights [36, 37] recorded for day
procedure stays to reflect the resources consumed during hospital
contacts. We converted these weights into Canadian dollars using a
multiplier known as the cost per weighted case [36, 37]. CKP cancer
from a known primary tumour, CUP cancer of unknown primary
tumour
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associated with higher risk of death and appeared to
account for most of the observed 31% increase in risk of
mortality for patients with CUP. This association should be
interpreted with caution as it might also be influenced by
unknown differences in tumour biologic behaviour, disease
burden and/or the functional status of patients between the
CUP and matched CKP groups [45]. However, no evidence
exists yet showing CUP tumours harbour distinct genetic
traits compared with CKP tumours [6, 46]. Thus, it might
be reasonable to infer that many patients were considered
unsuitable for more specific targeted cancer treatments and
were treated with more intensive empiric cytotoxic
chemotherapy due to the absence of knowledge about their
primary tumour site. Therefore, these data suggest that
identification of the primary tumour site early in the course
of metastatic disease may enable greater precision of
cancer therapy and potentially improve patients’ survival
by allowing patients with CUP to benefit more from
available healthcare resources during the ‘‘continuing
cancer care’’ phase, similar to their counterparts with CKP
[29].
Currently, a precision medicine approach can be applied
to the treatment of many metastatic cancers, including
cetuximab and panitumumab in colorectal cancer [27],
rituximab in lymphoma [47], bevacizumab in renal cell
carcinoma [48] and colorectal cancer [49], trastuzumab in
breast cancer [50], erlotinib in lung cancer [51] and sor-
afenib and sunitinib in renal cell carcinoma [52]. Knowl-
edge of the biologic characteristics of an individual tumour
(e.g. somatic EGFR, KRAS, ALK, HER2, BRAF, CD20, and
ROS1 gene status) is increasingly valuable in the clinical
management and treatment selection for patients with
metastatic cancer [27, 47–52]. However, the ability to
identify a primary tumour site is also increasingly impor-
tant and likely to remain important for the foreseeable
future [8]. For instance, knowledge of the primary tumour
site is needed to interpret somatic mutation results. Infor-
mation about KRAS mutation status has quite different
implications depending on whether the primary site is lung
versus colon [53]. Similarly, information regarding hor-
mone receptor status has quite different implications
depending on whether the primary tumour site is breast or
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Fig. 2 continued
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ovary. Generally, targeted therapies are studied, approved
and reimbursed solely within the context of an identified
primary tumour site [27, 47–52]. Furthermore, finding the
primary tumour site might prevent local complications (e.g.
bleeding from the primary tumour, obstruction or perfo-
ration of a viscus), give a better guide to prognosis and help
integrate patient-centred care into practice by helping the
physician communicate with the patient, who may also find
value in knowing where their cancer originated from,
independent of effects on prognosis and treatment [6, 46].
Therefore, information about the primary tumour site and
its inherent biologic characteristics are both valuable and
complementary in precision management of patients with
CUP [6, 46].
In our study, having CUP was associated with a sig-
nificant increase in the mean net cost of overall healthcare
utilization during the ‘‘initial diagnostic workup before
diagnosis’’ phase. Patients with CUP were also more likely
than those with CKP to receive several diagnostic tests and
procedures during the diagnostic workup. These findings
indicate that patients with CUP underwent more extensive
diagnostic investigations and incurred more costs to the
healthcare system related to difficulties in diagnosis.
Despite this, they remained without a primary tumour
classification following their clinical and pathologic diag-
nostic workup, according to our study of real-life Canadian
clinical practice. Although data about IHC investigation
were not available and thus our study was unable to
investigate pathological diagnostic barriers in these
patients, current Canadian clinical practice has not been
influenced by the availability of accurate gene expression
profiling assays to help identify the primary tumour in
metastatic cancer [1, 10, 54]. Our data suggest the need for
gene expression profiling techniques to complement cur-
rent traditional diagnostic procedures (e.g. IHC analyses,
endoscopies, CT scans, X-rays, MRI scans, etc.) when
dealing with diagnostic difficulties so that the primary
tumour can be classified early in the course of metastatic
disease. This may allow patients to avoid unnecessary or
even painful and distressing extensive investigations and
the healthcare system to avoid unnecessary costs. Recently,
the use of a gene expression profiling test to aid in iden-
tifying the primary tumour when current clinical and
pathological diagnostic evaluation failed to provide a
diagnosis of primary tumour site in CUP patients was
found to be cost effective from the Canadian healthcare
system perspective [34]. Our data further suggest some
value may be gained from using gene expression profiling
techniques at earlier stages in the diagnostic workup.
Although this is a retrospective cohort study and our
results must be interpreted with caution, the incidence of
CUP and the impact of primary tumour classification on
therapy, patient outcomes and cost of care throughout the
course of metastatic disease are unlikely to be studied in
prospective designed analyses or randomized controlled
trials. This is because CUP syndrome is extremely
heterogeneous and the ultimate study design would require
a very large sample size. Randomization to either site-
specific therapy or standard CUP empiric therapy following
primary tumour classification also may not be ethical
because it is already believed that, for many primary
tumour diagnoses, the standard empiric therapy for CUP
would be less effective. Our retrospective cohort study is
an example of an alternative approach.
This study used rigorous linkage of high-quality popu-
lation data from comprehensive heath administrative
databases and yielded a true incidence rate of CUP given
our strict inclusion criteria of histologically confirmed
metastatic disease and at least 6-month survival. We took
special care to avoid sources of bias and confounding in
our study by conducting a matched cohort analysis where
the matched group of patients with CKP clearly had the
same underlying population of Manitoba as patients with
CUP and were matched on all known patient and tumour
characteristics. In fact, the smaller number of patients
included in our matched cohort analysis compared with our
overall cohort permits future investigation of more detailed
and risk factors of having a CUP. For instance, important
factors associated with diagnostic workup obtained from
detailed medical histories or biologic markers such as
specialist referrals and type and frequency of immunohis-
tochemistry tests (i.e. information not collected by the
databases used for this study) become feasible to investi-
gate in order to understand the actual diagnostic barriers in
patients with CUP. Future studies can further link such
real-life cases with their specimens from banks of tumour
tissue samples to study the potential utility of personalized
diagnostic technologies such as the newly developed gene
expression profiling assays.
In addition, the diagnostic and prognostic parameters
and phase-specific cost estimates described in our study
represent key imputes necessary to build decision analytic
models designed to evaluate the cost effectiveness of such
personalized diagnostic technologies in CUP. Developing
these data is important to formulate new provincial
guidelines and reimbursement policies for CUP manage-
ment and is necessary to inform healthcare resource allo-
cation and fiscal planning for the prospective precision
medicine era of care for CUP. Thus, our data will ulti-
mately contribute in developing additional clinical evi-
dence to optimize a precision medicine strategy as a
standard of care for patients with CUP.
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5 Conclusion
CUP is the fifth most common cancer type diagnosed in
patients presenting with metastatic cancer and is more
common in women than in men. Compared with CKP
patients, CUP patients receive fewer site-specific and tar-
geted therapies but more empiric therapies, have reduced
OS, and use more healthcare resources for diagnostic
workup but less healthcare resources for cancer care.
Identifying the primary tumour in CUP patients might
enable the use of more precise anticancer therapy with the
goals of improving OS and more efficiently allocating
healthcare resources.
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